Histone variant MacroH2A1 is downregulated in prostate cancer and influences malignant cell phenotype - Vieira-Silva, T. S. (Portuguese Oncology Institute of Porto (IPO Porto)) ; Monteiro-Reis, S. (Portuguese Oncology Institute of Porto (IPO Porto)) ; Barros-Silva, D. (Portuguese Oncology Institute of Porto (IPO Porto)) ; Ramalho-Carvalho, J. (Portuguese Oncology Institute of Porto (IPO Porto)) ; Graça, I. (Portuguese Oncology Institute of Porto (IPO Porto)) ; Carneiro, I. (Department of Pathology. Portuguese Oncology Institute of Porto (IPO Porto)) ; Martins, A. T. (Department of Pathology. Portuguese Oncology Institute of Porto (IPO Porto)) ; Oliveira, Jorge (IPO-Porto. Department of Urology) ; Antunes, L. (Portuguese Oncology Institute of Porto (IPO Porto). Department of Epidemiology) ; Hurtado-Bagès, Sarah (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Buschbeck, Marcus (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Henrique, Rui (University of Porto. Department of Pathology and Molecular Immunology) ; Jeronimo, Carmen (University of Porto. Department of Pathology and Molecular Immunology) ; Universitat Autònoma de Barcelona